ChemPartner is well-equipped with a variety of cell-based assays including Histone H3 Methyltransferase, which enables us to examine epigenetic target engagement and the functional consequences in cells. We continually expand the scope of our technologies, including BacMan/GFP/TR-FRET so we are always on the forefront of epigenetics research.
In addition to the in vitro assays, we have also established over 100 xenograft models, many of which can be used in epigenetics studies. For instance, the SETDB1, CARM1 can be applied in breast cancer, and Ezh2, LSD1 for prostate cancer. These models have been used in compound testing for efficacy studies and PK/PD correlation.